Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
TORONTO –(BUSINESS WIRE)–Dec. 18, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
– Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors – – On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized
Cybin to Participate in the Jefferies Global Healthcare Conference in London
TORONTO –(BUSINESS WIRE)–Nov. 12, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
– Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 – TORONTO –(BUSINESS WIRE)–Nov. 6, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TORONTO –(BUSINESS WIRE)–Nov. 5, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
– Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 – TORONTO –(BUSINESS WIRE)–Nov. 3, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental
Cybin Announces Closing of $175 Million Registered Direct Offering
TORONTO –(BUSINESS WIRE)–Oct. 31, 2025– Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative
Cybin Announces $175 Million Registered Direct Offering
– Funding of Clinical Stage Programs with Participation from Prominent Biotech Investors – – Use of Proceeds Includes Repayment of High Trail Convertible Note in Full – TORONTO –(BUSINESS WIRE)–Oct. 28, 2025– Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
– Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Generalized Anxiety Disorder (“GAD”). Topline data expected Q1 2026 – – Continues to advance CYB003, the Company’s proprietary
Cybin to Participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
TORONTO –(BUSINESS WIRE)–Sep. 11, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today